Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

Inclusion Criteria: * be 40 - 70 years of age, inclusive * be seronegative for hepatitis B surface antigen (HBsAg), antibody against hepatitis B surface antigen (anti-HBsAg), antibody against hepatitis B core antigen (anti-HBcAg), and human immunodeficiency virus (HIV) * be in good health in the opinion of the investigator, based upon medical history, physical examination, and laboratory evaluation * if female of childbearing potential, agree to consistently use a highly effective method of birth control from screening visit through the treatment phase, for up to 28 days after the last injection Exclusion Criteria: * if female of childbearing potential, is pregnant, breastfeeding, or planning a pregnancy * has a history of or is considered by the investigator to be at high risk for recent exposure to HBV or HIV; for example, current intravenous drug use or has unprotected sex with known HBV/HIV positive partner * has a known history of autoimmune disease * has previously received any hepatitis B vaccine (approved or investigational)